Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer
Prostate-specific membrane antigen (PSMA) is highly expressed on most prostate cancer
(PCa) cells, and several PSMA ligands for PET imaging are now available worldwide. 68Ga …
(PCa) cells, and several PSMA ligands for PET imaging are now available worldwide. 68Ga …
Advanced prostate cancer: treatment advances and future directions
Prostate cancer affects one in every nine men in the USA and is the second leading cause of
cancer-related death. The treatment landscape of advanced prostate cancer is changing …
cancer-related death. The treatment landscape of advanced prostate cancer is changing …
E-PSMA: the EANM standardized reporting guidelines v1. 0 for PSMA-PET
Rationale The development of consensus guidelines for interpretation of Prostate-Specific
Membrane Antigen (PSMA)-Positron Emission Tomography (PET) is needed to provide …
Membrane Antigen (PSMA)-Positron Emission Tomography (PET) is needed to provide …
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients …
Purpose: Prostate specific membrane antigen-targeted positron emission tomography/
computerized tomography has the potential to improve the detection and localization of …
computerized tomography has the potential to improve the detection and localization of …
Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer
Background Preliminary trial results showed that enzalutamide significantly improved
metastasis-free survival among men who had nonmetastatic, castration-resistant prostate …
metastasis-free survival among men who had nonmetastatic, castration-resistant prostate …
[HTML][HTML] Apalutamide and overall survival in prostate cancer
MR Smith, F Saad, S Chowdhury, S Oudard… - European urology, 2021 - Elsevier
Background The phase 3 SPARTAN study evaluated apalutamide versus placebo in
patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and prostate …
patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and prostate …
[HTML][HTML] Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019
Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …
prostate cancer have improved outcomes, but there are still many aspects of management …
[HTML][HTML] Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer …
Background Innovations in imaging and molecular characterisation together with novel
treatment options have improved outcomes in advanced prostate cancer. However, we still …
treatment options have improved outcomes in advanced prostate cancer. However, we still …
Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA
B Feuerecker, R Tauber, K Knorr, M Heck, A Beheshti… - European urology, 2021 - Elsevier
Abstract Background Beta-emitting Lu-177-labeled prostate-specific membrane antigen
(PSMA) radioligand therapy (RLT) is a new option for metastatic castration-resistant prostate …
(PSMA) radioligand therapy (RLT) is a new option for metastatic castration-resistant prostate …
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
WP Fendler, M Eiber, M Beheshti, J Bomanji… - European journal of …, 2023 - Springer
Here we aim to provide updated guidance and standards for the indication, acquisition, and
interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics …
interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics …